Synedgen
Claremont, US · Delaware corporation
Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.
BiotechHealthtech
Founders & leadership
SB
Shenda BakerExecutive Officer, Director
WP
William P. WiesmannExecutive Officer, Director
KP
Kaveri ParkerExecutive Officer
LS
Laura SawardChief Executive Officer
PC
Paul C. GrintDirector
HO
Hal OienDirector
AW
Andrew W. MillerDirector
DB
Daniel BradburyDirector
KG
Kenton GregoryChief Medical Officer
CA
Clarke AtwellDirector
LS
Larry ShapiroDirector
DO
Diane OlmsteadDirector
Competitors · 7
by search overlapBiogen Idec17 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Solugen15 shared keywordsSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.
NervGen Pharma11 shared keywordsNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Diabetes Prevention Program11 shared keywords
Urogen10 shared keywords
TissueGen, Inc9 shared keywordsTissueGen develops drug delivery technologies that load sensitive biological therapeutics such as growth factors and antibodies into biodegradable fibers, microspheres, and other polymeric systems for slow, sustained release. Founded as a university spin-out, the company focuses on preserving biological activity during fiber extrusion to treat acute and chronic conditions.
Concord Communications9 shared keywords
Companies competing with Synedgen for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$1.8MraisedOct 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedOct 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shenda BakerExecutive Officer, Director
- William P. WiesmannExecutive Officer, Director
- Paul C. GrintDirector
- Hal OienDirector
- Andrew W. MillerDirector
- Daniel BradburyDirector
- Kaveri ParkerExecutive Officer
- Kenton GregoryDirector
- Offering amount
- $2M
- Amount sold
- $1.8M
- Proceeds to insiders
- $465K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJul 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedJul 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shenda BakerExecutive Officer, Director
- William P. Wiesmann, M.D.Executive Officer, Director
- Kenton Gregory, M.D.Director
- Paul Grint, M.D.Director
- Andrew W. MillerDirector
- Offering amount
- $3M
- Amount sold
- $2.5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2017 · 3 investors · PharmaceuticalsRule 506(b)
▶$3MraisedSep 2017 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenton Gregory, M.D.Director
- Shenda BakerExecutive Officer, Director
- William P. Wiesmann, M.D.Executive Officer, Director
- Robert CoughlinDirector
- Andrew W. MillerDirector
- Paul Grint, M.D.Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedNov 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenton GregoryDirector
- Paul GrintDirector
- Robert CoughlinDirector
- William WeismannExecutive Officer, Director
- Larry ShapiroDirector
- Andrew MillerDirector
- Shenda BakerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedApr 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$6MraisedApr 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul GrintDirector
- Shenda BakerExecutive Officer, Director
- Kenton GregoryDirector
- Larry ShapiroDirector
- Clarke AtwellDirector
- Diane OlmsteadDirector
- Andrew MillerDirector
- William WiesmannExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $6M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedMar 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedMar 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clarke AtwellDirector
- Larry ShapiroDirector
- William WiesmannExecutive Officer, Director
- Kenton GregoryDirector
- Diane OlmsteadDirector
- Andrew MillerDirector
- Shenda BakerExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $3.5M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2020 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $224.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $146.4K |
| Department of DefenseDefense Health Program | Phase II | 2014 | $870.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $196.7K |
| Department of DefenseDefense Health Program | Phase I | 2013 | $149.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $149.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $99.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $99.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.